Other Recent Articles

Mass Torts Update - Dec 2, 2014 11:08 - 0 Comments

Reglan Failure-To-Warn Claims Are Not Preempted

A decision by the New Jersey Appellate Division has preserved patients’ that manufacturers of generic Reglan failed to adequately warn about neurological risks associated with Reglan in use. The court said the companies had dragged their feet in updating the digestion medication’s labeling. The court ruled last month that federal law doesn’t preempt the . Continue…

More In Mass Torts

Product Liability - Dec 2, 2014 11:54 - 0 Comments

Korean Automakers Hyundai And Kia Agree To Record U.S. Settlement For Mileage Fraud

Hyundai Motor Co. and its affiliate Kia Motors Corp. have agreed to a $350 million settlement with the U.S. government related to charges the Korean automakers overstated the fuel efficiency of their vehicles. The settlement is being touted by government officials as the largest of its kind. The settlement comes after an investigation determined Hyundai-Kia had overstated the mileage figures on an estimated 1.2 million of its 2012 model vehicles. The settlement was announced Nov. 3. Continue…

More In Personal Injury

Drug Manufacturer Fraud Litigation - Dec 2, 2014 11:21 - 0 Comments

Unapproved Drugs In U.S. Market

The FDA drug approval process provides a review of product-specific information that is critical to ensuring the safety and efficacy of a finished drug product. However, there are prescription drugs currently available in the marketplace even though they have not been approved by the FDA. Many health care providers are unaware of the unapproved status of some drugs that are illegally marketed by the pharmaceutical companies and unknowingly prescribe these drug products. The FDA has serious concerns that drugs marketed without required FDA approval may not meet modern standards for safety, effectiveness, quality and labeling. Continue…

More In Fraud